Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

Blood (2025) 146 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2025-2350

Published: 2025

Journal Articles

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

Blood (2025) 146 (Supplement 1): 7631.

https://doi.org/10.1182/blood-2025-7631

Published: 2025

Journal Articles

The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease

Blood (2025) 146 (Supplement 1): 5895.

https://doi.org/10.1182/blood-2025-5895

Published: 2025

Journal Articles

Development of next generation multi-antigen targeting off-the-shelf CAR T cells for conditioning-free treatment of B-cell lymphoma

Shilpi Chandra, John Reiser, Brian Groff, Carissa Dege, Bryan Hancock, Alison O'Connor, Alma Gutierrez, Angela Gentile, Tom Lee, Ramzey Abujarour, Raedun Clarke, Betsy Rezner, John Goulding, Jode Goodridge, Karl-Johan Malmberg, Maksim Mamonkin, Bahram Valamehr, Alex Garcia, Martin Hosking

Blood (2025) 146 (Supplement 1): 4121.

https://doi.org/10.1182/blood-2025-4121

Published: 2025

Journal Articles

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, Rina Mbofung, Daniel Morales-Mantilla, Brian Groff, Alison O'Connor, Binzhong Li, Ramesh Janani, Betsy Rezner, Mark Jelcic, Yijia Pan, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, John Goulding, Jode Goodridge, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 503.

https://doi.org/10.1182/blood-2024-210846

Published: 2024

Journal Articles

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Blood (2022) 140 (23): 2451–2462.

https://doi.org/10.1182/blood.2021015184

Published: 2022

Includes: Supplemental data

Journal Articles

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Quirin Hammer, Karlo Perica, Rina M Mbofung, Hanna van Ooijen, Erika Varady, Mark Jelcic, Yijia Pan, Pouria Momayyezi, Brian Groff, Ramzey Abujarour, Silje Zandstra Krokeide, Tom Lee, Alan M Williams, Jode P Goodridge, Bahram Valamehr, Bjorn Onfelt, Michel Sadelain, Karl-Johan Malmberg

Blood (2022) 140 (Supplement 1): 1165–1166.

https://doi.org/10.1182/blood-2022-163086

Published: 2022

Journal Articles

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Alan M Williams, Ken L Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Amber Chang, Christine Chen, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Maksim Mamonkin, Raedun Clarke, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4547–4548.

https://doi.org/10.1182/blood-2022-167139

Published: 2022

Journal Articles

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Rina M Mbofung, Xingyue Zong, Erika Varady, Alan M Williams, Ken L Hayama, Yijia Pan, Sushil Devkota, Brian Groff, Miguel Meza, Thomas Dailey, Tom Lee, Lilly Wong, Sarah Cooley, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 7388–7389.

https://doi.org/10.1182/blood-2022-169817

Published: 2022

Journal Articles

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Quirin Hammer, Karl-Johan Malmberg, Maksim Mamonkin, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2021-153614

Published: 2021

Journal Articles

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

Rina M Mbofung, Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Thomas Dailey, Sonia Reyes, Sajid Mahmood, Ketan Mathavan, Greg Bonello, Quirin Hammer, Karl-Johan Malmberg, Tom Lee, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 2795.

https://doi.org/10.1182/blood-2021-153484

Published: 2021

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Ryan Bjordahl, PhD, Raedun Clarke, PhD, Svetlana Gaidarova, Matthieu Bauer, PhD, Jeff Sasaki, Brian Groff, Tom Lee, PhD, Weijie Lan, PhD, Ramzey Abujarour, PhD, Greg Bonello, PhD, Megan Robinson, Ian Hardy, PhD, Daniel Shoemaker, PhD, Bahram Valamehr, PhD

Blood (2017) 130 (Supplement 1): 3187.

https://doi.org/10.1182/blood.V130.Suppl_1.3187.3187

Published: 2017

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

Journal Articles

Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity

Blood (2016) 128 (22): 3363.

https://doi.org/10.1182/blood.V128.22.3363.3363

Published: 2016

Journal Articles

Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy

Raedun Clarke, PhD, Brian Groff, B.S., Jeffrey Sasaki, B.S., Matthieu Bauer, PhD, Tom Tong Lee, PhD, Weijie Lan, PhD, Michelle Burrascano, Ramzey Abujarour, PhD, Greg Bonello, Megan Robinson, BS, Heather Foster, David Robbins, BS, Scott Wolchko, MS, Daniel Shoemaker, PhD, Stewart E. Abbot, PhD BSc, MSc, Bahram Valamehr, PhD MBA

Blood (2016) 128 (22): 2164.

https://doi.org/10.1182/blood.V128.22.2164.2164

Published: 2016

Journal Articles

Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence By Overcoming the Host Histocompatibility Barrier

Matthieu Bauer, PhD, Raedun Clarke, PhD, Jeffrey Sasaki, B.S., Brian Groff, B.S., Tom Tong Lee, PhD, Weijie Lan, PhD, Ramzey Abujarour, PhD, Greg Bonello, Michelle Burrascano, Megan Robinson, BS, Ryan Bjordahl, PhD, Svetlana Gaidarova, M.S., Stewart E. Abbot, PhD BSc, MSc, Scott Wolchko, MS, Daniel Shoemaker, PhD, Bahram Valamehr, PhD MBA

Blood (2016) 128 (22): 2165.

https://doi.org/10.1182/blood.V128.22.2165.2165

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease

Development of next generation multi-antigen targeting off-the-shelf CAR T cells for conditioning-free treatment of B-cell lymphoma

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity

Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy

Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence By Overcoming the Host Histocompatibility Barrier

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only